Literature DB >> 9119229

Induction of c-myc transcription by the v-Abl tyrosine kinase requires Ras, Raf1, and cyclin-dependent kinases.

X Zou1, S Rudchenko, K Wong, K Calame.   

Abstract

v-Abl is an oncogenic form of the c-Abl nonreceptor tyrosine kinase. v-Abl induces transcription of c-myc, and c-Myc function is a necessary but not sufficient component of the v-Abl transformation program. Previously we showed that the E2F site in the c-myc promoter is a v-Abl response element and that v-Abl appears to induce c-myc by initiating a phosphorylation cascade that ultimately activates E2F-binding proteins. In this work we have investigated the signaling pathway between the v-Abl tyrosine kinase and activated E2F proteins. We show that the Ras GTPase and Raf1 serine/threonine kinase are required in this pathway. However, in contrast to other aspects of v-Abl signaling, induction of c-myc transcription is independent of the Rac GTPase. Our results also establish a requirement for activated cyclin-dependent kinases (cdks), as v-Abl-dependent induction of c-myc transcription is blocked by cdk inhibitor p21 and induction of c-myc is accompanied by activation of cdk2 and cdk4. Finally, we show that v-Abl-dependent induction of c-myc is accompanied by hyperphosphorylation of pRb, p107, and p130. On the basis of these data, we propose a model for the signaling path from v-Abl to c-myc.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9119229     DOI: 10.1101/gad.11.5.654

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  23 in total

1.  Nerve growth factor-induced cell cycle reentry in newborn neurons is triggered by p38MAPK-dependent E2F4 phosphorylation.

Authors:  Sandra M Morillo; Erika P Abanto; María J Román; José M Frade
Journal:  Mol Cell Biol       Date:  2012-05-14       Impact factor: 4.272

2.  Complementation of defective colony-stimulating factor 1 receptor signaling and mitogenesis by Raf and v-Src.

Authors:  N Aziz; H Cherwinski; M McMahon
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

3.  Role of c-fos and E2F in the induction of cyclin A transcription and vascular smooth muscle cell proliferation.

Authors:  A M Sylvester; D Chen; K Krasinski; V Andrés
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

4.  Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo.

Authors:  K R LaMontagne; A J Flint; B R Franza; A M Pandergast; N K Tonks
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

5.  p53 deficiency increases transformation by v-Abl and rescues the ability of a C-terminally truncated v-Abl mutant to induce pre-B lymphoma in vivo.

Authors:  X Zou; F Cong; M Coutts; G Cattoretti; S P Goff; K Calame
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

6.  NF-kappaB1 can inhibit v-Abl-induced lymphoid transformation by functioning as a negative regulator of cyclin D1 expression.

Authors:  Yukio Nakamura; Raelene J Grumont; Steve Gerondakis
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

7.  Temperature-sensitive transformation by an Abelson virus mutant encoding an altered SH2 domain.

Authors:  C A Mainville; K Parmar; I Unnikrishnan; L Gong; G D Raffel; N Rosenberg
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

8.  Changes in p19Arf localization accompany apoptotic crisis during pre-B-cell transformation by Abelson murine leukemia virus.

Authors:  Rebekah Stackpole Zimmerman; Naomi Rosenberg
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

9.  Absence of p53 complements defects in Abelson murine leukemia virus signaling.

Authors:  Indira Unnikrishnan; Naomi Rosenberg
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation.

Authors:  A Radfar; I Unnikrishnan; H W Lee; R A DePinho; N Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.